Title: Etoday-- About LegoChem Biosciences

Publication: Etoday/ Sung Heon Koo

Date: 20 May 2013

Summary

• Based on medicinal chemistry, LegoChem research-and-develops novel synthetic drugs and license-out to other companies.

• With excellent technology and growth potential, LegoChem became the 11th company to be publicly listed on KOSDAQ through New Growth Engine Company special evaluation.

• Since LegoChem possesses outstanding technology, expected demand for its stocks was exceptionally high.

• CEO Yong Zu Kim said “while promoting international awareness of the company through KOSDAQ IPO, LegoChem will try to become a global new drug development leader.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).